The purpose of this study is to determine the effect of four weeks of treatment with two investigational drugs (oral versus inhaled administration) plus an inhaled medication in the treatment of airway constriction brought on by exercise in asthmatic patients.

Condition	Intervention	Phase
Exercise-Induced Asthma	Drug: MK0476, montelukast sodium	Phase III

Ages Eligible for Study:  6 Years   -   14 Years,  Genders Eligible for Study:  Both

Criteria

Inclusion Criteria:

• 6-14 year old children with a history of asthma for at least 12 months.
• Patients must demonstrate airway constriction brought on by exercise.

Exclusion Criteria:

• Patient is taking any medications that are not allowed in the study.

Please refer to this study by ClinicalTrials.gov identifier  NCT00127166

Brazil, SP
      Merck Sharp & Dohme Farmaceutica Ltda., São Paulo,  SP,  04717-004,  Brazil
Colombia, Cundinamarca
      Frosst Laboratories Inc., Bogotá,  Cundinamarca,  Colombia
Estonia, Eesti
      Merck Sharp & Dohme IDEA, Inc., Tallinn,  Eesti,  11415,  Estonia
Greece
      Vianex, S.A. / MSD, Nea Erythrea,  146 71,  Greece
Italy
      Merck Sharp & Dohme (Italia) S.P.A., Roma,  191,  Italy
Korea, Republic of
      MSD Korea Ltd., Seoul,  121-705,  Korea, Republic of
Mexico, D.F.
      Merck Sharp & Dohme De Mexico, S.A. De C.V., Mexico,  D.F.,  1090,  Mexico
Netherlands
      Merck Sharp & Dohme B.V., Haarlem,  2031 BN,  Netherlands
Norway
      MSD (Norge) AS, DRAMMEN,  3011,  Norway
Peru, Lima
      Merck Sharp & Dohme, Perú S.R.L., Surquillo,  Lima,  LIMA 34,  Peru
Poland
      MSD Polska Sp. z o.o. Dzial Medyczny, Warszawa,  00-867,  Poland
Portugal
      Merck Sharp & Dohme Lda, Paço D''''arcos,  2770-192,  Portugal
Spain
      Merck Sharp & Dohme De Espana, S.A.E., Madrid,  28027,  Spain

Study chairs or principal investigators

Medical Monitor,  Study Director,  Merck   

Study ID Numbers:  2004_006
Last Updated:  August 19, 2005
Record first received:  June 30, 2005
ClinicalTrials.gov Identifier:  NCT00127166
Health Authority: Netherlands: Medicines Evaluation Board (MEB)
ClinicalTrials.gov processed this record on 2005-08-23